DHX15 and cancer: The helicase ‘active’ DHX15 is a crucial mediator of LOC action in driving MIF1-mediated TME reshaping, given that administration of a DHX inhibitor (YK-4-279) led to reduced migration of microglia (Fig. 4h,i) and macrophages (Extended Data Fig. 6d,e) towards IDH-wild-type cancer cells.